ArticleClinical & experimental metastasis2006
A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma.
Article in Clinical & experimental metastasis, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 103 citations in OpenAlex.
- New uses of halofuginone to treat cancer.Journal of pharmaceutical analysis · 2025Review
- Pigment Epithelium Derived Factor Is Involved in the Late Phase of Osteosarcoma Metastasis by Increasing Extravasation and Cell-Cell Adhesion.Frontiers in oncology · 2022Article
- Endothelial specific YY1 deletion restricts tumor angiogenesis and tumor growth.Scientific reports · 2020Article
- Article
- Isothiocyanates suppress the invasion and metastasis of tumors by targeting FAK/MMP-9 activity.Oncotarget · 2017Article
- Correlation study of DNA methylation of WNT6 gene with osteosarcoma in children.Oncology letters · 2017Article
- Overexpression of pyruvate kinase M2 predicts a poor prognosis for patients with osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review.Journal of experimental & clinical cancer research : CR · 2016Review
- Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.Oncotarget · 2015Article
- Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma.Journal of nanobiotechnology · 2015Article
- Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma.Frontiers in surgery · 2015Article
- Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics.Bioconjugate chemistry · 2014Article
- A polysaccharide from pomegranate peels induces the apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Biological characterization of preclinical Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model: A multi-modality approach.Journal of bone oncology · 2013Article
- Osteosarcoma models: from cell lines to zebrafish.Sarcoma · 2012Article
- Cell and molecular biology underpinning the effects of PEDF on cancers in general and osteosarcoma in particular.Journal of biomedicine & biotechnology · 2012Review
- Efficacy of continuously administered PEDF-derived synthetic peptides against osteosarcoma growth and metastasis.Journal of biomedicine & biotechnology · 2012Article
- Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model.British journal of cancer · 2011Article
- Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells.Investigational new drugs · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a reliable model for osteosarcoma is lacking, three human cell lines (SaOS-2, U2OS and 143B) were evaluated in cell-based assays for proliferation, adhesion, migration, invasion, anchorage-independent growth, angiogenesis, mineralised nodule formation, plasmid transfection and oligonucleotide transfection. Tumor take and metastasis after orthotopic injection of the three cell lines into mice was monitored. The levels of expression of typical bone markers were determined with semi-quantitative RT-PCR in cultured cells, primary tumors, and for the SaOS-2 cell line, the metastases. Tumors grew and spread to the lungs within 3 and 5 weeks respectively, mimicking the clinical progression of the disease as analysed by x-ray. Expression of molecular markers in SaOS-2 indicated a mostly differentiated cell type at the primary and secondary sites. The ability of osteosarcoma cells to interact with collagen-1 and to form mineralised deposits correlated positively with tumor aggression in vivo. Expression of alkaline phosphatase was a common theme in both tumor models at the primary site. The newly established SaOS-2 model should allow the testing of candidate anti-osteosarcoma agents as well as dissection of more intricate mechanisms involved in human osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.